Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia by Mansur, Marcela Braga et al.
RESEARCH ARTICLE Open Access
Impact of complex NOTCH1 mutations on survival
in paediatric T-cell leukaemia
Marcela Braga Mansur
1, Rocio Hassan
2, Thayana C Barbosa
1, Alessandra Splendore
3, Patricia Y Jotta
4,
José Andrés Yunes
4, Joseph L Wiemels
5 and Maria S Pombo-de-Oliveira
1,6*
Abstract
Background: Molecular alterations occur frequently in T-ALL and the potential impact of those abnormalities on
outcome is still controversial. The current study aimed to test whether NOTCH1 mutations and additional molecular
abnormalities would impact T-ALL outcome in a series of 138 T-ALL paediatric cases.
Methods: T-ALL subtypes, status of SIL-TAL1 fusion, ectopic expression of TLX3, and mutations in FBXW7, KRAS,
PTEN and NOTCH1 were assessed as overall survival (OS) and event-free survival (EFS) prognostic factors. OS and
EFS were determined using the Kaplan-Meier method and compared using the log-rank test.
Results: The frequencies of mutations were 43.5% for NOTCH1, while FBXW7, KRAS and PTEN exhibited frequencies
of 19.1%, 9.5% and 9.4%, respectively. In 78.3% of cases, the coexistence of NOTCH1 mutations and other molecular
alterations was observed. In multivariate analysis no statistical association was revealed between NOTCH1 mutations
and any other variable analyzed. The mean length of the follow-up was 68.4 months and the OS was 50.7%. SIL-
TAL1 was identified as an adverse prognostic factor. NOTCH1 mutation status was not associated with outcome,
while the presence of NOTCH1 complex mutations (indels) were associated with a longer overall survival (p =
0.031) than point mutations.
Conclusion: NOTCH1 mutations alone or in combination with FBXW7 did not impact T-ALL prognosis.
Nevertheless, complex NOTCH1 mutations appear to have a positive impact on OS and the SIL-TAL1 fusion was
validated as a negative prognostic marker in our series of T-ALL.
Background
T-cell Acute Lymphoblastic Leukaemia (T-ALL)
accounts for ~15% of all childhood ALL cases, and this
disease is clinically characterized as a high-risk malig-
n a n c yw i t har e l a p s er a t eo fa b o u t3 0 %[ 1 , 2 ] .T - A L Li s
also characterized by the occurrence of multiple genetic
alterations that result in the transformation of T-cell
precursors. Distinct immunophenotypic subsets and
somatic genetic alterations have been occasionally corre-
lated with prognosis, but these results could not be con-
sistently replicated by other studies, requiring larger
number of cases to confirm associations that could sup-
port an improvement in treatment [3-6].
S i n c et h ef i r s tr e p o r ta d d r e s s i n gt h er o l eo fNOTCH1
mutations in paediatric T-ALL prognosis, several
controversial issues have been raised regarding the
actual impact of these mutations on prognosis [7]. The
NOTCH1 gene is expressed in haematopoietic stem cells
(HSCs) and controls several steps of T-cell specification
and differentiation. This gene was first described in a
recurrent t(7;9)(q34;q34) chromosomal translocation
rarely found in T-ALL [8], and recently the gain-of-
function NOTCH1 mutations were reported as a com-
mon event in T-ALL patients (~50%) [9]. These muta-
tions mainly involve the heterodimerization (HD)
domain, the C-terminal PEST/TAD domain, or both,
resulting in up-regulation of Notch1 signalling [9,10].
However, the significance of each type of NOTCH1
mutation and especially their impact on disease recur-
rence remains to be investigated.
Additional molecular markers are not often included
in prognostic studies limiting the evaluation of
NOTCH1 mutations as an independent prognostic fac-
tor. Few studies have examined the prognostic role of
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Genetic lesions targeting multiple cellular pathways
including T-lymphoid development, tumour suppression
(FBXW7) and cell cycle regulation, as well as PI3-
kinase/Akt (PTEN)a n dR a s( KRAS) signalling appear to
be central events in the pathogenesis of T-ALL [11].
Given this evidence, we hypothesized that analysis of
NOTCH1 in concert with genes functionally related to
Notch1 pathway, such as FBXW7, KRAS and PTEN,
would provide additional relevant information regarding
T-ALL prognosis. We therefore explored associations
between the NOTCH1 mutations patterns and other
somatic alterations in paediatric T-ALL cases in an
attempt to better understand the relationship with dis-
ease progression and outcome.
Methods
Subjects
A series of 138 paediatric T-ALL were selected for this
study from 178 cases, from January 2001 to January
2008, based on the availability of biological material for
molecular analysis. Subjects were ascertained from four
geographical regions assembled by a national network of
acute leukaemia studies [12] and the majority of cases
were included in a previous publication [6]. The exclu-
sion criteria applied for the analysis was age (12
months) and the diagnosis of T-lymphoblastic lym-
phoma according to WHO classification [13,14].
Diagnostic samples were obtained prior to any che-
motherapy regimen and provided along with demo-
graphic and clinical data of each patient. Peripheral
blood (PB) samples, typically with high white blood cell
(WBC) count, were send along with BM aspirates. The
presence or absence of blast cells in the BM aspirate
and PB was reviewed before molecular analysis. To leu-
kaemia diagnosis a threshold of >20% of blast cells in
the BM was used as lower limit for analysis. In the PB,
a clinically high WBC count or a blast percent ≥50%
were considered suitable for our analysis.
Ethical aspects
The Ethical and Scientific Committees of the Instituto
Nacional de Câncer, Rio de Janeiro, Brazil approved the
study (CEP-INCA#107/06) in accordance with the
Declaration of Helsinki ethical standards.
Demographic and clinical data
Characteristics of patients obtained at diagnosis were
age, gender, mediastinum involvement and elevated
WBC counts. The participants’ ethnicities were categor-
ized according to the skin colour, as Whites and non-
Whites. There were 60 (43.5%) patients self reported as
Whites and 78 (56.5%) as non-Whites. In the non-
White category blacks and all mixed-populations were
included, according to criteria described elsewhere [15].
T h ea g er a n g ew a s≥1-18 years-old, which was divided
in two groups for data analysis as < 10 and 10-18 years-
old. Eighty six cases (62.3%) were from the Northeast
region of Brazil, 34 (24.6%) from the Southeast, 15
(10.9%) cases from Central plateau; and 3 (2.2%) from
the South region.
One-hundred and one patients were treated according
to Brazilian Group for Treatment of Childhood Leukae-
mia (GBTLI-99), while 37 were treated according to the
ALL-Berlin-Frankfurt-Munster (BFM) protocols back-
bone strategies, as described elsewhere [16,17].
Immunological characterization
In all cases, the diagnosis was established according to
criteria previously defined [13,14]. After mononuclear
cell separation using Ficoll-Hypaque-Hystopaque
®,
immunophenotype was performed in blast cells by flow
cytometry using a defined panel of monoclonal antibo-
dies, as previously described [6] and/or by immunohis-
tochemistry methods [13,14]. Immunological
classification of T-ALL was based on criteria previously
published by the European Group for the Immunologi-
cal Characterization of Leukaemias [18].
Nucleic acids extraction and cDNA synthesis
Genomic DNA was extracted from BM aspirate by one
of the following methods: the QIAamp
® DNA Blood
Mini Kit (Qiagen GmbH, Hilden, Germany) (n = 78),
ethanol precipitation from phenol phase after RNA iso-
lation (n = 36), or the salting out method (n = 24).
F o rR T - P C R sa s s a y s ,t h et o t a lR N Aw a sp r e p a r e d
using the TRIzol reagent kit (Invitrogen, Carlsbad, Cali-
fornia, USA) according to the manufacturer’si n s t r u c -
tions (n = 129). cDNA was generated by reverse
transcription of 2 μg of total RNA using First-Strand
cDNA Synthesis Kit™ (Amersham Biosciences UK Lim-
ited, Little Chalfont, UK), and stored at −20°C. The
integrity of cDNA was examined by amplifying a frag-
ment of the GAPDH constitutive gene, according to
reported conditions [6].
NOTCH1 mutations
NOTCH1 mutations were analyzed by screening of the
heterodimerization (HD) and polypeptide enriched in
proline, glutamate, serine and threonine (PEST) domains
according to procedures described previously [9]. In
general, PEST and TAD domains are both denominated
PEST domain. In summary, the N-terminal region of
the HD domain of NOTCH1, encoded by exon 26, was
divided in two amplicons. The amplification of exon 27,
encoding the C terminal region of NOTCH1 HD
domain, resulted in one amplicon; and sequences of
exon 34 encoding the PEST domain and the contiguous
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three amplicons. All six amplicons were sequenced on
both strands. Mutations were classified into two groups:
complex and point mutations. Complex mutations were
defined as insertions and/or deletions (also called as
indels) in the gene sequence, and point mutations as
single base changes. A case was considered to harbour
complex mutation when an indel was detected alone or
concomitant with point mutations. Classification in mis-
sense or nonsense mutations was in accordance with
classical mutation definition.
FBXW7 mutations
To evaluate the mutational status of FBXW7,w e
screened the exons 9 and 10, previously reported to be
the most frequently mutated regions [19,20]. We per-
formed PCR reactions for each exon with specific pri-
mers. PCR products were purified and then directly
sequenced. All procedures for FBXW7 screening were
described elsewhere [20].
SIL-TAL1 and TLX3 assays
The SIL-TAL1 fusion and TLX3 (also known as
HOX11L2) presence were investigated according to pre-
viously published methods [21,22]. PCR products of
both RT-PCR assays were separated by 1.5% agarose gel
electrophoresis, stained with ethidium bromide.
KRAS mutations
To study the mutations in codons 12 and 13 of the
KRAS gene were carried out separate PCR reactions for
each codon, using 100 ng of genomic DNA. PCR pro-
ducts from codon 12 were digested with restriction
enzyme using NE Buffer 2, 100 μg/ml BSA and 10U of
BstNI (Biolabs, New England, MA), and incubated over-
n i g h ta t6 0 ° C .T h eP C Rp r o d u c t so fc o d o n1 3w e r e
digested with 2U of PflMI for 6 h at 37°C. The digested
PCR fragments were visualized on a 3% agarose gel, as
previously described [23]. All the mutations found with
restriction fragment length polymorphism- RFLP assay
were confirmed by direct sequencing.
PTEN mutations
PTEN sequences of exons 1 and 7 were amplified by
PCR. Conformational analysis was performed by hetero-
duplex assays, followed by direct DNA sequencing to
confirm abnormal patterns, as described elsewhere [24].
PCR products were sequenced on both strands using
the BigDye kit (Applied Biosystems).
Statistical analysis
Univariate p values were calculated using Pearson’s chi-
square test. Mann-Whitney test was used to test median
differences of continuous variables. Two-sided p values
with a significance limit of 0.05 were used throughout
the study. The probability of overall survival (OS) was
determined using the Kaplan-Meier method in months
from the diagnosis to outcome (death, alive or last fol-
low-up). Patients lost to follow-up were censored at
their date of last known contact. Event-free survival
(EFS) was the interval (in months) from diagnosis to
progression at any time, relapse from complete
response, or initiation of new, previously unplanned
treatment or to the last follow-up in the patients with
treatment success. The differences between T-ALL sur-
vival distributions were compared by the log-rank test.
The multivariate Cox proportional hazard regression
method was used to determine the independent prog-
nostic factors influencing OS and EFS. Multivariate Cox
analysis was performed with variables associated with a
p ≦ 0.1 in univariate analysis such as the type of
NOTCH1 mutation (point vs. complex mutations), SIL-
TAL1 fusion and induction responses. SPSS (Statistical
Product and Services Solutions, version 18.0, SPSS Inc,
Chicago, IL, USA) software was used for data analyses.
Results
The main demographic, clinical, and molecular charac-
teristics of T-ALL cases according to NOTCH1 status
are shown in Table 1. The median age of the total series
of cases was 8 years (1-18 years), and a predominance
of males was observed, with a 2.6:1 male/female ratio.
Immunophenotyping analyses by flow cytometry were
available for 130 cases, and in 8 cases the T-cell diagno-
sis were confirmed by immunohistochemistry with
CD45
+/CD3
+. Regarding T-cell maturation, we observed
a predominance of T-IV subtype (38.0%). Overall, 60/
138 patients (43.5%) presented with NOTCH1 muta-
tions; additional molecular alterations observed were
FBXW7 mutations (21/110; 19.1%), SIL-TAL1 fusion
(37/129; 28.7%), TLX3 ectopic expression (10/119; 8.4%),
KRAS (10/105; 9.5%) and PTEN mutations (9/96; 9.4%).
In 78.3% of cases, the coexistence of NOTCH1 muta-
tions and other molecular alterations was observed,
including FBXW7 (n = 13), SIL-TAL1 (n = 19), TLX3 (n
= 6), PTEN (n = 5), and KRAS (n = 4) mutational. How-
ever, no statistical association was disclosed between
NOTCH1 mutations status and any other variable
analyzed.
n number of cases, mut mutated, wt wild-type, WBC
white blood cells count at diagnosis.
a 8 cases without
information about mediastinal mass, being 4 with
NOTCH1 mutation and 4 wild-type;
b classification
according to EGIL criteria, flow cytometry was not per-
formed in 8 cases, 2 presented NOTCH1 mutation and
6 wild-type;
c there were 22 cases without CD10 status
evaluated, 7 with NOTCH1 mutation and 15 wild-type;
pos, positive; neg, negative
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same signalling pathway, patients with mutations in
both genes (NOTCH1 and/or FBXW7)w e r ea n a l y z e d
together as a NOTCH1-FBXW7 mutated group. In total,
62 patients (56.4%) presented with NOTCH1-FBXW7
mutations. Patients with FBXW7, KRAS or PTEN muta-
tions shared other molecular alterations along with
NOTCH1 mutations, such as FBXW7 mutation and SIL/
TAL1 (n = 5), FBXW7 mutation and TLX3 (n = 1),
FBXW7 and KRAS mutations (n = 2), FBXW7 and
PTEN mutations (n = 1). We also observed KRAS muta-
tion and SIL/TAL1 (n = 1), KRAS mutation and TLX3
(n = 2), PTEN mutation and SIL-TAL1 (n = 1), PTEN
and KRAS (n = 1), and one case exhibited PTEN, KRAS
and SIL-TAL1 alterations.
T h ec o m p l e t ed e s c r i p t i o n so fNOTCH1 mutations
sequences in HD and PEST domains are shown in Addi-
tional file 1: Table S1. Single nucleotide polymorphism
(SNP) already described, recurrent mutations as well as
previously unreported mutations were observed. Thirty-
eight new mutations were found in the HD domains
and 15 in PEST domain, representing 63.1% (53/84) of
all mutations found. Among these new mutations there
were no SNPs, since we have checked and excluded any
SNP possibility through NCBI SNP database and 1000
genomes data. The NOTCH1 SNPs found in this work
have been excluded from all subsequent mutation ana-
lyses; and they were mentioned in Additional file 1:
Table S1 only for descriptive purposes.
The main demographic and clinical features of T-
ALL patients with different types of NOTCH1 muta-
tions are summarized in Table 2. Mutations were not
randomly distributed, with a predominance of point
mutations in the HD domain, and complex mutations
in the PEST domain (p = 0.014). Also, nonsense muta-
tions were more frequent in the PEST domain and
missense mutations in the HD domain (p < 0.0001).
Seven cases presented with mutations in both HD and
PEST domains, with a predominance of complex muta-
tions (22.2%). No significant statistical differences were
observed with respect to age groups, gender and T-
ALL subtypes, in respect to any type of NOTCH1
mutation. High WBC was observed in patients har-
bouring complex mutations, while patients with point
mutations exhibited lower WBC (p = 0.035). Point
mutations were more frequent in non-white patients (p
= 0.053); where a higher frequency of mutations in the
HD domain was observed (89.7% versus only 10.3% in
PEST domain, p = 0.028). Missense mutations were
more frequent in CD10+ cases (p = 0.042). Eleven out
of 14 nonsense mutations were caused by complex
mutations, the other three by point mutations. Thirty
out of 46 missense mutations were caused by point
mutations and the remaining 16 by complex mutations
(p = 0.004, data not shown).
Overall survival of the 138 cases was 50.7% (Figures
1A). Mean length of the follow-up was 68.4 months
(95% CI 58.9-77.8 months). For 68 patients who evolved
to death, the follow-up was 0-76 months (median 9),
with 9 deaths occurring in the first 3 days after diagno-
sis and 57.4% of deaths (39 patients) occurring in the
first 12 months of treatment. For 70 patients alive, the
follow-up was 15-124 months (median 73.5), with 75%
of patients with 94.5 months follow-up. No differences
in OS were observed in patients treated with GBTLI or
BFM-based protocols (52.5% vs. 45.9%, respectively; p =
0.639).
Table 1 Clinical, demographic and laboratorial features
of T-ALL patients according to NOTCH1 status, 2001-2008
Variable n (%) NOTCH1 mut n
(%)
NOTCH1 wt n
(%)
p
value
Age (Years)
< 10 71 (51.4) 28 (46.7) 43 (55.1) 0.324
10-18 67 (48.6) 32 (53.3) 35 (44.9)
Gender
Male 100
(72.5)
46 (76.7) 54 (69.2) 0. 332
Female 38 (27.5) 14 (23.3) 24 (30.8)
WBC (×10
9/L)
<50 63 (45.7) 29 (48.3) 34 (43.6) 0.579
≥50 75 (54.3) 31 (51.7) 44 (56.4)
Mediastinal
mass
a
Yes 58 (44.6) 24 (42.9) 34 (45.9) 0.726
No 72 (55.4) 32 (57.1) 40 (54.1)
Skin colour
White 60 (43.5) 21 (35.0) 39 (50.0) 0.078
Non-white 78 (56.5) 39 (65.0) 39 (50.0)
T-ALL
subtypes
b
T-I 18 (13.8) 9 (15.5) 9 (12.5) 0.343
T-II 29 (22.3) 9 (15.5) 20 (27.8)
T-III 34 (26.2) 18 (31.0) 16 (22.2)
T-IV 49 (37.7) 22 (37.9) 27 (37.5)
CD10 status
c
positive 36 (31.0) 16 (30.2) 20 (31.7) 0.857
negative 80 (69.0) 37 (69.8) 43 (68.3)
Molecular
Studies
SIL-TAL1
pos
37 (28.7) 19 (32.8) 18 (25.4) 0.355
HOX11L2
pos
10 (8.4) 6 (11.1) 4 (6.2) 0.332
FBXW7
mut 21 (19.1) 13 (24.1) 8 (14.3) 0.192
KRAS
mut 10 (9.5) 4 (7.7) 6 (11.3) 0.527
PTEN
mut 9 (9.4) 5 (10.9) 4 (8.0) 0.630
Total 138
(100)
60 (100) 78 (100)
Mansur et al. BMC Cancer 2012, 12:9
http://www.biomedcentral.com/1471-2407/12/9
Page 4 of 11T h er e s u l t so ft h eO Su n i v a r i a t ea n a l y s e so fT - A L L
cases considering variables such as age, WBC at onset
of disease, T-ALL cellular subtypes, CD10 expression,
skin colour, response to induction therapy, mutational
status of NOTCH1, FBXW7, NOTCH1-FBXW7 group,
KRAS and PTEN,p r e s e n c eo fSIL-TAL1 fusion, and
ectopic expression of TLX3 are shown in Table 3, Figure
1 and Additional file 2: Figure S1.No statistically signifi-
cant impact in OS was found for the following variables:
age, WBC, T-ALL subtypes, CD10 expression, skin col-
our, mutational status of FBXW7, KRAS and PTEN,a n d
ectopic expression of TLX3.
Test of equality of survival distribution for the differ-
ences of NOTCH1 status (mutated vs. wild-type) showed
no statistical significant results (53.3% vs. 48.7%; p =
0.479). On the other hand, carriers of NOTCH1 complex
mutations (indels) exhibited a favourable OS when com-
pared with carriers of point mutations (66.7% vs. 42.4%;
p = 0.031; HR 2.33, CI95% 1.05-5.18) (Figures 1B),
NOTCH1 wild-type patients showed an intermediate OS
rate (48.7%). OS differences between complex and point
NOTCH1 mutations were more marked in the patients
treated with the BFM protocols backbone strategies
(27.3% vs. 62.5%; p = 0.041). For NOTCH1-FBXW7
combined mutations no impact on OS was observed
(58.1% vs. 47.9%), mutated in NOTCH1-FBXW7 vs. WT;
p = 0.319 showed in Figure 1C.
T h ep r e s e n c eo fSIL-TAL1 fusion was predictive of a
worse outcome (OS 37.8% vs. 56.5%; p = 0.012; HR
1.89, CI95% 1.13-3.17) (Figure 1D). Multivariate Cox
analysis showed that the type of NOTCH1 mutations
(point vs. complex mutations) was not an independent
prognostic factor (p = 0.769), compared with SIL-TAL1
fusion (p = 0.04; HR 2.87; 95% CI 1.39-5.92) and induc-
tion response (p = 0.10; HR 2.69; 95% CI 1.27-5.71),
even when adjusted by treatment protocol.
Table 2 Main demographic and clinical features of T-ALL patients according to type and classification of NOTCH1
mutations
Variables Point Mutations
a (%) Complex Mutations n (%) p value Missense n (%) Nonsense n (%) p value
Age (Years)
< 10 14 (42.4) 14 (51.9) 0.466 21 (45.7) 7 (50.0) 0.775
10-18 19 (57.6) 13 (48.1) 25 (54.3) 7 (50.0)
Gender
Male 26 (78.8) 20 (74.1) 0.668 34 (73.9) 12 (85.7) 0.361
Female 7 (21.2) 7 (25.9) 12 (26.1) 2 (14.3)
WBC (x10
9/L)
<50 20 (60.6) 9 (33.3) 0.035 23 (50.0) 6 (42.9) 0.640
≥50 13 (39.4) 18 (66.7) 23 (50.0) 8 (57.1)
Skin colour
White 8 (24.2) 13 (48.1) 0.053 15 (32.6) 6 (42.9) 0.481
Non-white 25 (75.8) 14 (51.9) 31 (67.4) 8 (57.1)
T-ALL subtypes
b
T-I 4 (12.9) 5 (18.5) 0.825 8 (17.8) 1 (7.6) 0.589
T-II 4 (12.9) 5 (18.5) 6 (13.3) 3 (23.1)
T-III 10 (32.3) 8 (29.6) 15 (33.3) 3 (23.1)
T-IV 13 (41.9) 9 (33.3) 16 (35.6) 6 (46.2)
CD10 status
c
Positive 11 (39.3) 5 (20.0) 0.127 15 (37.5) 1 (7.7) 0.042
Negative 17 (60.7) 20 (80.0) 25 (62.5) 12 (92.3)
NOTCH1 mutated domain
HD 28 (84.8) 14 (51.9) 0.014 38 (82.6) 4 (28.6) <0.0001
PEST/TAD 4 (12.1) 7 (25.9) 4 (8.7) 7 (50.0)
Both domains 1 (3.0) 6 (22.2) 4 (8.7) 3 (21.4)
FBXW7status
d
Mutated 6 (20.0) 7 (29.2) 0.434 11 (27.5) 2 (14.3) 0.320
WT 24 (80.0) 17 (70.8) 29 (72.5) 12 (85.7)
Total 33 (100) 27 (100) 46 (100) 14 (100)
a insertions and/or deletions; WBC, white blood cells count;
b classification according to EGIL criteria, flow cytometry was not performed in 2 cases with
mutations, both were classified as point/missense;
c CD10 status was not available in 7 cases, being 5 with point mutations and 2 complex; and 6 classified as
missense and 1 as nonsense;
d FBXW7 mutational status was not performed in 28 cases out of 138, 22 of 28 were WT, 3 presented point mutations and 3
complex mutations, all 6 mutations were classified as missense
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(day 30-33) was recorded, with 52.5% of cases exhibiting
induction failure, independent on protocol allocation. Of
the 38 cases that achieved clinical remission, 26 (72.5%)
maintained the initial response and 12 (27.5%) relapsed
during maintenance therapy and died. Of 42 cases with
induction failure 11 (26.2%) evolved to death and the
remaining 31 were submitted to re-induction therapy
(14 with secondary remission).
Induction therapy response was significantly associated
with a longer overall survival, both in univariate and
multivariate analyses (p < 0.0001; HR 2.86; 95% CI 1.38-
5.94) as shown in Table 3. However, no significant asso-
ciation was found between any of the molecular altera-
tions and induction response (data not shown).
Ninety-five patients had sufficient clinical data for
conducting EFS analysis (9 cases that evolved to death
previously to treatment due to severity of disease were
excluded of this analysis). All variables evaluated in the
OS analysis were also included in EFS investigations.
Results of EFS analysis are described in Table 3.
EFS exhibited no difference according to NOTCH1-
FBXW7 status (40.5% Mutated, 48.5% WT, p = 0.286)
(Figure 2A). For patients bearing complex NOTCH1
mutations the EFS was better than for those presenting
point mutations (30.4%, 40% respectively, p = 0.289),
albeit not statistically significant (Figure 2B). EFS was
significantly worse in patients bearing SIL-TAL1 (18.2%
vs. 43.8%; p = 0.004) (Figure 2C), and also in those
patients with no response to induction therapy (32.4%
(A)
(C)
(B)
(D)
Figure 1 Kaplan-Meier overall survival curves for T-ALL patients. (A) Overall survival (OS) of T-ALL patients. In this analysis were included all
138 patients with T-ALL. (B) NOTCH1 type of mutation (point mutations vs. complex mutations) OS curve. For the construction of this curve
were included all 60 patients with NOTCH1 mutations, being 33 patients harbouring point mutations and 27 complex mutations. (C) OS curve for
NOTCH1-FBXW7 status. In this Kaplan-Meier OS curve were analyzed 110 T-ALL patients with NOTCH1-FBXW7 status determined, 62 with NOTCH1-
FBXW7 mutations and 48 displaying WT profile. (D) OS according to the presence or absence of SIL-TAL1 fusion gene. Symbols represent
censored cases. The SIL-TAL1 fusion OS analysis included 129 T-ALL cases, being 37 SIL-TAL1+ and 92 SIL-TAL1-.
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analysis identified only SIL-TAL1 (HR 3.12; 95% CI
1.48-6.57) and induction failure (HR 3.07; 95% CI 1.44-
6.55) as independent negative prognostic factors.
Discussion
In a previous analysis, we compared the presence of
CD1a
+ve phenotype, SIL-TAL1 status, TLX3 abnormal
expression and the clinical features on the impact in the
Table 3 Univariate analysis of overall (OS) and event-free survival (EFS) in T-ALL patients
Variables OS
a (95% CI) p
b HR
c (Lower-Upper) EFS
a (95% CI) p
b HR
c (Lower-Upper)
Age (Years)
< 10 45.1 (48.9-74.5) 0.275 0.77 (0.48-1.24) 28.8 (30.8-57.8) 0.044 0.58 (0.34-1.00)
10-18 56.7 (60.7-88.0) 51.2 (51.9-85.8)
WBC (x10
9/L)
<50 47.6 (51.6-79.4) 0.606 0.88 (0.55-1.42) 41.3 (40.9-73.3) 0.859 1.05 (0.63-1.76)
≥50 53.3 (57.1-82.5) 36.7 (39.2-68.5)
EGIL
T-I 33.3 (28.8-77.2) 0.411 0.93 (0.74-1.18) 31.3 (26.9-75.9) 0.954 0.98 (0.77-1.24)
T-II 51.7 (48.2-88.7) 36.4 (31.5-75.5)
T-III 61.8 (56.1-90.7) 45.0 (32.9-78.6)
T-IV 51.0 (44.0-70.9) 36.7 (30.2-60.9)
CD10
Positive 52.8 (50.6-86.9) 0.696 1.12 (0.63-1.97) 48.1 (42.6-83.6) 0.097 1.67 (0.89-3.08)
Negative 50.0 (54.1-79.4) 28.8 (31.6-59.5)
Skin colour
White 55.0 (54.5-81.5) 0.451 1.20 (0.74-1.96) 33.3 (32.1-61.5) 0.331 0.78 (0.46-1.30)
Non-white 47.4 (52.8-77.8) 43.4 (45.9-75.9)
NOTCH1
Mutated 53.3 (54.6-80.8) 0.479 1.19 (0.73-1.93) 34.2 (30.5-60.9) 0.382 0.79 (0.47-1.34)
WT 48.7 (52.7-78.2) 42.1 (45.5-74.2)
Type of mutation
Point 42.4 (32.4-61.9) 0.031 0.43 (0.19-0.95) 30.4 (19.1-51.4) 0.289 0.65 (0.28-1.47)
Complex 66.7 (65.6-100.9) 40.0 (31.4-79.4)
FBXW7
Mutated 61.9 (54.8-102.3) 0.512 1.28 (0.60-2.73) 58.3 (38.9-104.9) 0.586 1.29 (0.51-3.31)
WT 51.7 (59.2-82.3) 41.4 (47.2-74.7)
NOTCH1-FBXW7
Mutated 58.1 (62.5-89.6) 0.319 1.32 (0.76-2.28) 40.5 (37.6-72.3) 0.286 0.71 (0.37-1.34)
WT 47.9 (50.7-82.3) 48.5 (51.1-87.7)
SIL-TAL1
Positive 37.8 (32.1-68.3) 0.012 0.53 (0.32-0.88) 18.2 (11.9-48.7) 0.004 0.46 (0.26-0.81)
Negative 56.5 (60.9-81.9) 43.8 (46.4-71.1)
HOX11L2
Expressed 40.0 (13.4-44.6) 0.469 0.74 (0.32-1.71) 50.0 (14.3-50.2) 0.806 1.14 (0.41-3.16)
Absent 48.6 (54.1-75.2) 35.6 (39.3-63.6)
KRAS
Mutated 60.0 (32.7-78.1) 0.585 1.32 (0.48-3.67) 57.1 (21.4-79.7) 0.584 1.38 (0.43-4.46)
WT 49.5 (55.7-77.9) 36.9 (41.5-66.9)
PTEN
Mutated 44.4 (15.1-56.1) 0.359 0.65 (0.26-1.66) 30.8 (34.6-66.1) 0.693 0.31 (0.53-1.51)
WT 57.5 (63.5-86.6) 42.0 (41.0-71.8)
Induction Response
d
Yes 68.4 (76.2-106.9) <0.001 3.45 (1.74-6.85) 70.3 (75.5-107.7) <0.001 3.54 (1.71-7.32)
No 33.3 (25.9-55.9) 32.4 (23.4-48.6)
a Survival in percent;
b Mantel-Cox (log-rank) test;
c last category used as reference;
d evaluated in day 30-33 of treatment; HR hazard risk, WT wild-type, WBC
white blood cells count
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Page 7 of 11prognosis of T-ALL in series of Brazilian children and
young adults [6]; whereas the presence of SIL-TAL1 had
a poor outcome, particularly in younger children, either
ectopic TLX3 or immunophenotyping were not predic-
tive factors for outcome corroborating with data
described by the Dutch Childhood Oncology Group
[25]. Albeit, molecular alterations such as SIL-TAL1,
TLX3,a n dNOTCH1 mutations have been reported as
T-ALL prognostic factors, due to scarce studies world-
wide, most of them have inconsistent results
[3,10,25,26].
Investigation of NOTCH1 mutations and their rela-
tionships with T-cell specific markers is still relevant
because of its importance as a potential therapeutic tar-
get and prognostic marker [27]. In this context, the
current study is one of the largest homogenous series of
T-ALL childhood patients incorporating NOTCH1
mutation screening. Overall the NOTCH1 mutations
were not correlated with variables considered as prog-
nostic factors such as, age range, T-cell subtypes or
other molecular aberrations. However, new interesting
information concerning the association between WBC
count and type of NOTCH1 mutation was observed (p =
0.035). This finding cannot be compared with other
data, since there is no similar analysis reported on the
literature.
The frequency of NOTCH1 mutation in our series of
patients was 43.5%, which is consistent with the results
of previously reported clinical series, that showed muta-
tion frequencies between 31 and 62%, depending on the
(A)
(C)
(B)
(D)
Figure 2 Kaplan-Meier event-free survival curves (EFS) for T-ALL patients. For the EFS endpoint we performed survival analysis in 95 out of
138 T-ALL patients. (A) EFS curve for patients harbouring NOTCH1-FBXW7 mutations vs. WT cases. In the construction of this EFS curve were
included 70 patients, 37 with NOTCH1-FBXW7 mutations and 33 WT. (B) EFS according to the type of NOTCH1 mutations (complex vs. point). This
curve is corresponding to analysis of 38 patients with EFS and NOTCH1 type of mutations available data. Twenty-three patients presented point
mutations and 15 complex mutations. (C) SIL-TAL1 fusion negative impact on EFS. Eighty-six patients were analyzed for SIL-TAL1 prognostic role
in EFS, 22 SIL-TAL1+ and 64 SIL-TAL1-. (D) EFS of patients that respond to induction compared to those without response. Symbols represent
censored cases. For the construction of this EFS curve were analyzed 71 patients, being 37 with induction response and 34 with no response.
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mutation screening found 33 point-mutations and 27
complex-mutations. Fifty-three previously unreported
unique NOTCH1 mutations were found in our series of
Brazilian patients. In the NOTCH1 literature reports, the
description of new mutations is a relatively frequent
event [3,25,28-30]. To exclude false-positive results lead-
ing to the large number of new mutations, direct
sequencing analyses were performed in different labora-
tory conditions and the same mutations were amplified
with concordant results proving that contamination was
unlikely. Moreover, NOTCH1 mutation profile concern-
ing the domain affected (HD, PEST, or both) and type
of mutations (point or complex) agreed with previously
reported molecular analysis [3,10].
Associations between NOTCH1 mutations and out-
come have been inconsistent in different series of cases
[7]. This discrepancy may be due to differences in the
therapeutic protocols for each series. We have not
found significance on prognosis for NOTCH1 status
(mutated vs. WT) in our T-ALL cases, and this finding
is in accordance to major T-ALL studies [9,25,28]. Addi-
tionally we found that complex mutations were asso-
ciated with a longer survival time than point mutations
(p = 0.031), although the impact of mutation type did
not stand as a prognostic factor for EFS. We believe
that this lack of significance in the EFS analysis could
be due to the small number of patients (n = 38) with
EFS and NOTCH1 type of mutations available data.
Then, we indicate the need to replicate this finding in
an independent group of patients. Given the distinct
functional effects of different mutations in NOTCH1
domains [7,9], our results raises the issue of the poten-
tial differential role of NOTCH1 mutation in the course
of disease. Although no functional study has addressed
this issue, we speculate that complex mutations would
alter the Notch1 protein structure more drastically than
point mutations, so blast cells would be more vulnerable
to therapy responses. It is also possible that, as complex
mutations were seen associated with high WBC, cases
with complex mutations their presence lead to an initial
more aggressive treatment, and hence to a sustained
survival.
Key pathways related to Notch1 include the Ras/MAP
Kinase and PI3-kinase/Akt. For the Ras/MAP Kinase
pathway, since the majority of the studies evaluated the
impact of KRAS mutations in mouse models with T-cell
neoplasia [31,32], our KRAS data provides additional
information in the evaluation of frequency and prognos-
tic impact of these mutations in the largest described
series of T-ALL patients. We found it in 9.5% of cases,
without any impact on outcome. For the crosstalk
between PI3-kinase/Akt and Notch1 pathways is
described that Notch1 signalling via Hes1 down-
regulates PTEN, an important negative regulator of PI3-
kinase/Akt signalling [33]. Even with clear functional
interaction between NOTCH1 and PTEN genes, no asso-
ciation for mutational status of these genes was found.
Regarding the survival analysis, PTEN mutations dis-
played no statistically significance impact in OS or EFS
(Table 3). Our results are in agreement with those of
Gutierrez et al. [34], but are discordant with previous
Brazilian results [24], which found a negative prognostic
impact of PTEN mutations in T-ALLs. This variance
may be due to the different classification of mutations
(biallelic vs. monoallelic vs. wild-type) performed by
Jotta et al. [24], indicating that the role of PTEN muta-
tions as prognostic markers in T-ALL patients is not yet
fully defined.
Mutations affecting FBXW7 in leukemic cells mediate
Notch1 pathway activation [35]. Since NOTCH1 and
FBXW7 mutations lead to the same effect, the hypoth-
esis that T-ALL with FBXW7 mutations would be clini-
cally similar to those with activating NOTCH1
mutations is reasonable [20]. Based on this idea, we per-
formed a joint mutational analysis for these genes and
our data of NOTCH1-FBXW7 mutation rate was 56.4%
of T-ALLs, which is in line with previous reports on
childhood T-ALL [35,36]. Concerning survival analysis,
NOTCH1-FBXW7 mutational status showed no statisti-
cally significant impact on OS and EFS analysis. This
absence of significance on OS and EFS analysis is con-
cordant with other previously described results in repre-
sentative series of paediatric T-ALL [19,20,37].
We have previously shown that SIL-TAL1 was an age-
dependent prognostic factor, when rare cases of T-ALL
in children with less than 1 year-old were included [6].
However, the present analysis excluding such young
cases demonstrates that SIL-TAL1 is an independent
adverse prognostic factor in older children as well.
Conclusion
In our series the status of NOTCH1 mutations alone or
in combination with FBXW7 did not impacted in T-
ALL prognosis. Nevertheless, NOTCH1 complex muta-
tions were associated with a longer T-ALL overall survi-
val, and SIL-TAL1 was validated as a marker of worse
prognosis. These data should be tested in other series of
cases to confirm the relevance of such analyses.
Additional material
Additional file 1: Table S1. Detailed descriptions of all NOTCH1
mutations sequences according to domain involved.
Additional file 2: Figure S1. Kaplan-Meier overall survival curves for T-
ALL patients. (A) Overall survival (OS) according to the presence of KRAS
mutations. One hundred and five cases were included in this analysis, 10
with KRAS mutated and 95 WT. (B) OS according to the presence of
PTEN mutations. In the PTEN OS analysis were included 96 patients,
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Page 9 of 11being 9 with mutations and 87 WT. (C) OS according to the expression
of the TLX3 gene. For the construction of this OS curve, 119T-ALL cases
were analyzed, 10 TLX3+ and 109 TLX3-(D) OS of patients treated with
GBTLI (Brazilian Group for Treatment of Childhood Leukaemia)
therapeutic protocol compared with ALL-BFM (Berlin-Frankfurt-Munster)
protocols backbone strategies. Symbols represent censored cases. All 138
cases were included for Treatment Protocol OS analysis, 101 treated
according GBTLI and 37 according BFM.
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